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Abstract 
The differences between women’s and men’s experiences of health and illness are well known. Gender-specific 
medicine needs to restore equilibrium in order to understand the different clinical signs, diagnostic procedures, 
and therapeutic needs of diseases in men and women. This new dimension of medicine needs investment in 
research and health policy. If health professionals and healthcare organizations do not systematically take gender 
differences into account, inequities may arise and endure. Most discussions of gender involving an ethical 
perspective begin with the argument that women and men should be regarded as being of equal moral value. 
Where there are no relevant differences between them, then fairness and justice dictate that they should be 
treated equally, but if differences in needs exist, service planning should take this into account. Under these 
circumstances, equity as well as equality should be a guiding principle. The promotion of greater equality 
between men and women has also become a crucial issue in the bioethical debate, even if there is some 
confusion about the meaning of equality in this context, and especially of how this can be obtained. Biological 
differences cannot be removed, but their potentially harmful effects can be mitigated through social policies that 
take them properly into account, and through health research, policies and projects that give due attention to 
gender considerations and promote gender equity between women and men. 
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Introduction 
Gender medicine is the study of the influence of sex 
(in the biological sense) and of gender (in the social 
sense) on physiology, pathophysiology and on 
diseases. It aims at reaching decisions and evidence-
based treatments for both men and women, and is 
concerned with the study of the differences in the 
medical field, in terms of prevention, clinical 
manifestations, therapeutic approaches, prognosis, 
psychological and social impact [1].  
The terms ‘sex’ and ‘gender’ are often used 
interchangeably, but the two concepts have different 
meanings. ‘Sex’ refers to the biologically determined 
differences between males and females; a definition 
that may appear, by means of a superficial 
interpretation, relatively simple. An individual’s sex is 
represented by complex chromosomal characteristics, 
internal and external genitalia, hormone balance and 
secondary sexual characteristics. 
The term ‘gender’, on the other hand, refers more 
strictly to psychological aspects, social and cultural 
rights. It involves the circumstances of a person’s life, 
the belief that each person has in him or herself and 
the behavior that men and women have in the social 
sphere, how they appear, how they think, what they 
feel, how they dress and how they perceive the world 
in which they live. 
According to the World Health Organization [2], the 
term ‘gender’ should describe those characteristics of 
women and men that are socially constructed, while 
the term ‘sex’ should refer to biologically determined 
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aspects. People are born male or female, but learn to 
be girls and boys, and then grow into women and 
men. This learned behavior constitutes gender identity 
and determines social gender roles. 
In biomedical sciences, gender medicine implies the 
study of gender-related differences, not only with 
regard to anatomical and physiological aspects, as 
functionality and clinical response to treatments, but 
also with particular attention to the psychological 
implications, and to social and cultural rights. 
 
Medical aspects  
The health differences between men and women are 
well known in the literature, and significant 
differences exist in mortality and morbidity rates. It is 
interesting to note that the nature of these gender 
differences vary between different countries and, 
within the same country, vary between different 
regions and different social groups [3, 4].  
The distribution of diseases and the related morbidity 
rate is very variable: it is evident that women are at 
greater risk for certain transmittable infectious 
diseases, such as malaria and HIV, or for non-
transmittable diseases such as depression, anxiety and 
arthritis. On the contrary, men have a greater risk of 
suffering from traumatic injuries and problems related 
to substance abuse or addiction. 
Some examples of how gender medicine applies to 
clinical practice come from cardiology, oncology and 
internal medicine [5, 6]. Women live longer than men, 
but a greater level of disability often mars the quality 
of life associated with this greater survival. In 
addition, over the past 30 years there has been a 
significant decline in mortality from cardiovascular 
diseases in men but not in women [1]. 
In terms of oncological pathologies, women exhibit 
differences in the effectiveness of drugs related to 
metabolic diversity, have a different manifestation of 
symptoms of certain types of cancer with the same 
histologic features and staging, a different impact of 
comorbidities, and different consequences of tumors 
in the relational, social, and familial spheres [7]. 
Clinical data suggest that men and women show 
differences in the epidemiology and progression of 
some diseases, such as liver disease, autoimmune 
diseases, genetic hemochromatosis, non-alcoholic 
steatohepatitis, chronic hepatitis C and osteoporosis 
[1, 8]. 
Women remain under-represented in Phase 1 and 2 
clinical trials. Pharmacokinetic analysis, which is 
performed during these stages, would be useful to 
detect potential differences in dosage required to 
prevent side effects, contributing to greater drug 
effectiveness in each patient [9]. Consequently, 
medicine applied to women is less evidence-based 
than that applied to men. Even the recruitment of 
women in Phase 3 studies has been poor [10]; 
however, over the past decade there have been 
requests from authorities to reduce gender differences 
in research [11, 12].  
Possible solutions could arise from requests for 
justification as to why different numbers of males and 
females are proposed for these studies, thereby 
encouraging the publication of studies in which both 
sexes are adequately represented. In addition, drug 
agencies should ensure that physicians and patients 
are aware of the differences between the sexes in 
terms of dosage and reactions to medications. 
An emblematic example of how gender differences 
affect experimentation in biomedicine is that of 
clinical studies on the effect of drugs in pregnancy: 
pregnant women get sick just as sick women get 
pregnant. To enlist pregnant women in clinical trials is 
certainly problematic for numerous reasons, but health 
protection requires the avoidance of situations where, 
in the absence of information, physicians prescribe 
drugs to pregnant women while knowing very little or 
even nothing at all about them, or even not prescribe 
them at all. 
 
Implications for practice and policy  
The promotion of greater equality between men and 
women has become a crucial issue not only in the 
bioethical debate but also in the international socio-
political field, despite the persistency of confusion 
about the meaning of the term ‘equality’ in this 
context and, more importantly, on how this might be 
achieved. 
 ‘Gender equality’ and ‘gender equity’ are both widely 
used in literature analyzing gender differences and 
             www.ame-journal.com   Caenazzo et al. 2015 | 2:5 3 
their implications for biomedicine. It is, however, 
worth pointing out some issues on the difference 
between the two definitions and their practical 
implications. 
Most discussions of ‘gender justice’ assume that men 
and women should be considered of equal moral 
value, and in this light it is interesting to analyze the 
position of Payne and Doyal [13]: if one admits that 
there are no major differences between genders, then 
respect for the principle of justice should require men 
and women to be treated equally. This means that men 
and women should have equal access to the same 
tools and the same services in all spheres of personal 
and social life. Therefore, assuming the absence of 
differences between genders, both equality (equality) 
and fairness (equity) should be pursued. 
However, reflecting on the field of biomedicine, 
where it is clear there are gender differences of social 
or biological nature, which affect individuals’ ability 
to protect their health, then any biomedical application 
that does not take these differences into account 
would be unfair and certainly productive of inequality. 
In the area of health, the planning and management of 
services should take gender differences into account 
[14, 15]. 
Despite an initial and general preference for the term 
‘gender equality’ in health policy, some international 
organizations have started to use the term ‘gender 
equity’ instead because this expression seems to more 
properly reflect the importance of biological and 
social differences in influencing morbidity and 
mortality in men and women.  
The key objective in biomedicine and health 
programming on a local and global scale is not gender 
equality per se, but the recognition of the different 
needs of men’s and women’s health by virtue of their 
differences: that is gender equity that should be 
guaranteed in health policies. 
The reason why it seems to be more appropriate – in 
the context of the management of health policies, 
unlike other areas – to apply gender equity with 
respect to gender equality, resides in the inevitable 
physiological differences between biologically male 
and biologically female subjects. 
Biology and physiology are determining factors in the 
promotion and protection of health and the lack of 
recognition of differences can create more inequality 
between men and women. Of course, biological 
differences cannot be removed, but their potential 
harmful effects, for one group over another, can be 
prevented with health policies that properly take them 
into account, with a view to equity rather than 
equality. Moving from this concept, whichever 
strategy is applied – starting from a condition of 
equality in gender diversity – an achievable goal in 
medicine is to ensure that both men and women have 
the opportunities to maximize their health potential, 
with respect to their biological diversity, and it is in 
this context that strategies to achieve a condition of 
gender equity must take into account differing health 
needs. 
Compared with their mothers, most women today are 
better educated and participate more consistently in 
working life. Reflecting on their general state of 
health, this fact is because of a slow but progressive 
education towards ‘gender sensitivity’ (in medicine). 
In turn, this is owed more to a cultural matrix than to 
health awareness, but it nevertheless shows that an 
education spread throughout life and a consequent 
level of autonomy and self-consciousness is functional 
to a global process for achieving gender equity. 
Life and human health are not only results, but they 
are first of all of assets. They are not products, but 
values for the individual and for society. Therefore, in 
a deontological and ethical sense, the professional 
responsibility lies not so much with securing a result, 
but in making a commitment towards an asset such as 
life and health. 
This commitment, in an ethical perspective, is not 
only a commitment to the means to achieve a goal, but 
an approach for global benefit; becoming important 
for all health professions to be aware of the 
importance of a gender-based approach to medicine, 
and also in structuring future versions of codes of 
conduct as an educational tool to raise awareness and 
knowledge on these issues. Sensitivity towards gender 
issues, however, is the result of a process of education 
and health organization, which today is still lacking, 
and cannot be exhausted only in the ethical debate. 
In clinical practice, the recognition of gender 
medicine implies being formed with a ‘gender 
sensitivity’, which is the expertise of health 
professionals in identifying existing gender 
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differences and incorporating these in the decision-
making process of care and treatment. 
 
Conclusions 
To create sustainable changes that will improve 
people’s health and quality of life, efforts on the part 
of governmental and non-governmental structures in 
terms of health programming should be directed 
towards achieving ‘gender equity’,  
Given the magnitude of the problem, a bioethical 
discussion on this topic could encourage the pursuit of 
gender equity in healthcare and promote the full 
recognition of women’s rights to health. This could be 
one of the most effective and direct ways to reduce 
inequalities and to ensure a rational and efficient use 
of resources. 
All gender differences, both in clinical and research 
settings, should be taken into account in the various 
aspects of health planning, including those related to 
healthcare professionals’ education, as well as 
education within the general population. The 
widespread diffusion of what we might call ‘gender 
sensitivity’ would, in this way, be structured through 
healthcare professionals and population education, 
and through the design and implementation of more 
adequate healthcare policies, oriented to the pursuit of 
gender equity. 
It is necessary to find models, such as a reference in 
the healthcare professionals’ code of ethics, which 
could include the above-mentioned considerations. A 
greater ethical dialogue between professional men and 
women is important to be of help in the relationship 
between professionals, and between professionals and 
patients, on the basis of a relationship typically 
understood as that between one person and another, in 
consideration of equalities and differences. 
A shared reflection that takes into account not only 
the biologically and epidemiologically relevant 
differences among genders, but also the main 
determinants of health under an ethical perspective, 
may find a role in a structured education to diversity, 
sensitivity and gender equity. 
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